ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BMS compounds go to Biogen, Roche

by Michael McCoy
April 17, 2017 | APPEARED IN VOLUME 95, ISSUE 16

Bristol-Myers Squibb has struck separate agreements to license BMS-986168, an anti-eTau compound in development for progressive supranuclear palsy, to Biogen and BMS-986089, an antimyostatin adnectin in development for Duchenne muscular dystrophy, to Roche. Biogen will pay $300 million plus milestones of up to $410 million. Roche will pay $170 million plus milestones of up to $205 million. BMS says the deals will allow it to prioritize other drugs in its pipeline. It got BMS-986168 with its 2014 acquisition of iPierian.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment